The Business Research Company’s report on the Glaucoma Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How have key drivers contributed to the rapid growth of the glaucoma market?
The rising prevalence of chronic eye conditions is expected to propel the growth of the glaucoma market going forward. Chronic eye conditions are long-term disorders that affect the eyes, often causing persistent vision impairment or discomfort and requiring ongoing management or treatment. Chronic eye conditions are rising due to aging populations, increased screen time, lifestyle factors, and a higher prevalence of conditions like diabetes and hypertension. Glaucoma treatment is required for chronic eye conditions to lower intraocular pressure, prevent further optic nerve damage, and preserve vision, as untreated glaucoma can lead to irreversible blindness. For instance, in December 2024, according to the National Health Service (NHS), a UK-based publicly funded healthcare system, over 2 million people in the UK are living with sight loss in 2024. Further, the number of people living with sight loss is projected to increase by 27%, reaching approximately 2.8 million by 2035. Therefore, the rising prevalence of chronic eye conditions is driving the glaucoma market.
Access Your Free Sample of the Global Glaucoma Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp
How has the glaucoma market size evolved, and what are the latest forecasts for its expansion?
The glaucoma market size has grown strongly in recent years. It will grow from $7.76 billion in 2024 to $8.22 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increasing awareness of eye health, increasing healthcare spending, growing adoption of telemedicine for eye care, expanding healthcare infrastructure, increase in government healthcare initiatives.
The glaucoma market size is expected to see strong growth in the next few years. It will grow to $10.20 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to aging population, rising prevalence of glaucoma, growing demand for minimally invasive surgeries, rising prevalence of diabetes, rising prevalence of hypertension. Major trends in the forecast period include advancements in diagnostic technologies, availability of new drug treatments, technological innovations in surgical devices, availability of combination therapies, adoption of robotic surgeries.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp
Which major companies dominate the glaucoma market?
Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG
What trends will shape the future of the glass fiber reinforced plastic (gfrp) composites market?
Major companies operating in the glaucoma market are focusing on developing innovative therapies, such as Rho-kinase (ROCK) inhibitors, to offer a dual mechanism of action, reducing intraocular pressure through both enhanced outflow of aqueous humor and the relaxation of trabecular meshwork cells, making them effective in treating glaucoma. Rho-kinase (ROCK) inhibitors are a class of drugs that target and block the activity of Rho-kinase enzymes, which regulate cell contraction and treat glaucoma to reduce intraocular pressure. For instance, in July 2023, Santen Pharmaceutical Co. Ltd., a Japan-based eye care products company, launched Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) of latanoprost and netarsudil, a novel Rho-kinase (ROCK) inhibitor, that effectively reduces intraocular pressure (IOP) by targeting trabecular meshwork dysfunction. It is indicated for adult patients with primary open-angle glaucoma or ocular hypertension who have not achieved adequate IOP reduction with monotherapy using a prostaglandin or netarsudil. The introduction of Roclanda in Europe marks the first new class of glaucoma medication in 25 years, offering a breakthrough in treatment. By combining netarsudil and latanoprost, Roclanda works synergistically to increase outflow through trabecular (conventional) and uveoscleral (unconventional) pathways, providing a comprehensive approach to managing elevated IOP.
Which region dominates the glaucoma market, and what factors contribute to its leadership?
North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report
How is the glaucoma market segmented, and which segment holds the largest share?
The glaucoma market covered in this report is segmented –
1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types
2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy
3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes
4) By Administration: Oral, Injections, Intravitreal, Other Administrations
5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma
2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma
3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20820
How is the glaucoma market defined?
Glaucoma is a group of eye disorders that cause damage to the optic nerve, typically resulting from increased intraocular pressure (IOP). This damage can lead to progressive, irreversible vision loss if untreated, making glaucoma one of the leading causes of blindness worldwide. Glaucoma is a leading cause of blindness worldwide, and early detection through regular eye exams is critical to prevent vision loss.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
